Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vistagen Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $123.29 Mil. Vistagen Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $131.07 Mil.
Therefore, Vistagen Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.94.
The historical rank and industry rank for Vistagen Therapeutics's Equity-to-Asset or its related term are showing as below:
VTGN'
s Equity-to-Asset Range Over the Past 10 Years
Min: -76.09 Med: 0.42 Max: 0.94
Current: 0.94
During the past 13 years, the highest Equity to Asset Ratio of Vistagen Therapeutics was 0.94. The lowest was -76.09. And the median was 0.42.
VTGN's Equity-to-Asset is ranked better than 93.61% of 1564
companies
in the Biotechnology industry
Industry Median: 0.66
vs VTGN: 0.94
Vistagen Therapeutics Equity-to-Asset Historical Data
The historical data trend for Vistagen Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vistagen Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Vistagen Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's Equity-to-Asset falls into.
Vistagen Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vistagen Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vistagen Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Vistagen Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Vistagen Therapeutics (Vistagen Therapeutics) Business Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your 